{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:25:19Z","timestamp":1789046719276,"version":"build-2803163510"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination (HR)-deficient tumors. Nevertheless, their clinical utility is often compromised by the emergence of resistance. Although genetic restoration of HR is a well-established resistance mechanism, emerging evidence suggests that epigenetic and chromatin responses are also central determinants of cell survival under PARPi-induced stress. Indeed, PARP inhibition drives the acute depletion of H3-H4 histones, thereby creating a cellular reliance on efficient histone recycling to ensure genome integrity. The histone chaperone Nuclear Autoantigenic Sperm Protein (NASP) has recently been implicated as a critical regulator in this process by sequestering evicted histones from degradation and promoting chromatin recovery. This NASP-dependent histone turnover may be particularly relevant to cancer stem cell (CSC) biology, as CSCs rely on dynamic chromatin plasticity to switch between phenotypic states and resist therapy. In this review, we focus on the intersection of histone dynamics and CSC survival, with particular emphasis on the ATP-dependent chromatin remodeler inositol-requiring mutant 80 (INO80), the NASP histone maintenance axis, and histone chaperones such as Facilitates Chromatin Transcription (FACT) as potential therapeutic targets. Targeting these chromatin maintenance pathways may provide new opportunities to overcome PARPi resistance and limit the persistence of resistant CSC subpopulations, although further experimental validation is required.<\/jats:p>","DOI":"10.3389\/fphar.2026.1914271","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:20:21Z","timestamp":1789042821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chromatin adaptation and histone remodeling as mechanisms of PARP inhibitor resistance and therapeutic vulnerability"],"prefix":"10.3389","volume":"17","author":[{"given":"Woori","family":"Bae","sequence":"first","affiliation":[{"name":"Department of Biochemistry & Molecular Pharmacology, New York University Grossman School of Medicine","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun A.","family":"Ra","sequence":"additional","affiliation":[{"name":"Institute for Cell Engineering, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Department of Neurology, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myon Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology Division, Brody School of Medicine at East Carolina University","place":["Greenville, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30504","DOI":"10.1074\/jbc.M111.264721","article-title":"The histone chaperone facilitates chromatin transcription (FACT) protein maintains normal replication fork rates","volume":"286","author":"Abe","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.molmed.2021.04.010","article-title":"Studying PAR-dependent chromatin remodeling to tackle PARPi resistance","volume":"27","author":"Andronikou","year":"2021","journal-title":"Trends Mol. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1093\/nar\/gkac303","article-title":"NASP maintains histone H3-H4 homeostasis through two distinct H3 binding modes","volume":"50","author":"Bao","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1158\/1541-7786.MCR-18-0594","article-title":"PARP inhibition induces enrichment of DNA repair-proficient CD133 and CD117 positive ovarian cancer stem cells","volume":"17","author":"Bellio","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9653244","DOI":"10.1155\/2022\/9653244","article-title":"Cancer stem cells: from an insight into the basics to recent advances and therapeutic targeting","volume":"2022","author":"Bisht","year":"2022","journal-title":"Stem Cells Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1093\/nar\/gkv1372","article-title":"The histone chaperone sNASP binds a conserved peptide motif within the globular core of histone H3 through its TPR repeats","volume":"44","author":"Bowman","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11038","DOI":"10.18632\/oncotarget.2701","article-title":"Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer","volume":"5","author":"Burkhart","year":"2014","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","article-title":"The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors","volume":"84","author":"Cadzow","year":"2024","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4161\/nucl.28067","article-title":"Dynamics of histone variant H3.3 and its coregulation with H2A.Z at enhancers and promoters","volume":"5","author":"Chen","year":"2014","journal-title":"Nucleus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1016\/j.molcel.2021.07.015","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1055028","DOI":"10.3389\/fmmed.2022.1055028","article-title":"Cancer cell targeting by CAR-T cells: a matter of stemness","volume":"2","author":"D'Accardo","year":"2022","journal-title":"Front. Mol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.10.011","article-title":"The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma","volume":"468","author":"Fehling","year":"2020","journal-title":"Cancer Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"14563","DOI":"10.1073\/pnas.1821475116","article-title":"Replication fork stalling elicits chromatin compaction for the stability of stalling replication forks","volume":"116","author":"Feng","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.cub.2014.07.077","article-title":"Histone H3.3 is required to maintain replication fork progression after UV damage","volume":"24","author":"Frey","year":"2014","journal-title":"Curr. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/cancers15061897","article-title":"DNA repair and therapeutic strategies in cancer stem cells","volume":"15","author":"Gillespie","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.chembiol.2023.12.019","article-title":"PARP trapping is governed by the PARP inhibitor dissociation rate constant","volume":"31","author":"Gopal","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.molcel.2020.12.006","article-title":"Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD","volume":"81","author":"Hewitt","year":"2021","journal-title":"Mol. Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12929-021-00743-5","article-title":"Histone dynamics during DNA replication stress","volume":"28","author":"Hsu","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1101\/gad.264150.115","article-title":"Histone H3.3 maintains genome integrity during mammalian development","volume":"29","author":"Jang","year":"2015","journal-title":"Genes Dev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1101\/gad.1547707","article-title":"Nucleosome stability mediated by histone variants H3.3 and H2A.Z","volume":"21","author":"Jin","year":"2007","journal-title":"Genes Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"eabb8626","DOI":"10.1126\/sciadv.abb8626","article-title":"The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment","volume":"6","author":"Juhasz","year":"2020","journal-title":"Sci. Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","article-title":"Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts","volume":"9","author":"Kolesnichenko","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.sbi.2013.01.003","article-title":"PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis","volume":"23","author":"Langelier","year":"2013","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"103059","DOI":"10.1016\/j.sbi.2025.103059","article-title":"Structure and function of histone chaperones in replication-coupled chromatin assembly","volume":"92","author":"Liu","year":"2025","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-023-39846-y","article-title":"Histone H1 facilitates restoration of H3K27me3 during DNA replication by chromatin compaction","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41586-026-10404-y","article-title":"Two decades of PARP inhibitor synthetic lethality in cancer","volume":"653","author":"Lord","year":"2026","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13072-024-00550-w","article-title":"Transcriptional regulation mechanism of PARP1 and its application in disease treatment","volume":"17","author":"Lu","year":"2024","journal-title":"Epigenetics Chromatin"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","article-title":"NASP modulates histone turnover to drive PARP inhibitor resistance","volume":"645","author":"Moser","year":"2025","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1002\/jcp.27740","article-title":"Cancer stem cells (CSCs) in cancer progression and therapy","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell Physiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2023.12.019","article-title":"Poly(ADP-ribosyl)ation enhances nucleosome dynamics and organizes DNA damage repair components within biomolecular condensates","volume":"84","author":"Nosella","year":"2024","journal-title":"Mol. Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"189440","DOI":"10.1016\/j.bbcan.2025.189440","article-title":"Cancer stem cells in focus: deciphering the dynamic functional landscape of stemness in cancer","volume":"1880","author":"Nwokolo","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","article-title":"H3.3(K27M) cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas","volume":"32","author":"Pathania","year":"2017","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110376","DOI":"10.1016\/j.isci.2024.110376","article-title":"Astragalus polysaccharides sensitize ovarian cancer stem cells to PARPi by inhibiting mitophagy via PINK1\/Parkin signaling","volume":"27","author":"Peng","year":"2024","journal-title":"iScience"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.molcel.2025.08.017","article-title":"RAD51 is chromatin enriched and targetable in BRCA1-deficient cells","volume":"85","author":"Peng","year":"2025","journal-title":"Mol. Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cancers15010006","article-title":"Epigenetic insights on PARP-1 activity in cancer therapy","volume":"15","author":"Pinton","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1038\/s41388-020-1346-9","article-title":"Histone chaperone FACT is essential to overcome replication stress in mammalian cells","volume":"39","author":"Prendergast","year":"2020","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An effective Epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1038\/s41467-024-50673-7","article-title":"Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells","volume":"15","author":"Ramakrishnan","year":"2024","journal-title":"Nat. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.molcel.2018.08.010","article-title":"Accurate recycling of parental histones reproduces the histone modification landscape during DNA replication","volume":"72","author":"Reveron-Gomez","year":"2018","journal-title":"Mol. Cell"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.64898\/2026.02.26.708215","volume-title":"FACT Depletion Results in a Temporal Cascade of Chromatin Disruption Preceding Transcriptional Collapse in Stem Cells","author":"Sankar","year":"2026"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2020.11.027","article-title":"The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma","volume":"499","author":"Tallman","year":"2021","journal-title":"Cancer Lett."},{"key":"B55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fmolb.2020.00079","article-title":"Cancer stem cell plasticity - a deadly deal","volume":"7","author":"Thankamony","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA damage as a source of genomic instability in cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41594-022-00747-1","article-title":"PARP inhibition impedes the maturation of nascent DNA strands during DNA replication","volume":"29","author":"Vaitsiankova","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1011882","DOI":"10.3389\/fmmed.2022.1011882","article-title":"Targeting epigenetic alterations in cancer stem cells","volume":"2","author":"Verona","year":"2022","journal-title":"Front. Mol. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.stemcr.2020.11.002","article-title":"Histone modifications in stem cell development and their clinical implications","volume":"15","author":"V\u00f6lker-Albert","year":"2020","journal-title":"Stem Cell Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e2407426","DOI":"10.1002\/advs.202407426","article-title":"Chromatin organization governs transcriptional response and plasticity of cancer stem cells","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s12276-026-01673-8","article-title":"PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge","volume":"58","author":"Wang","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101151","DOI":"10.1016\/j.drup.2024.101151","article-title":"CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer","volume":"77","author":"Xue","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11412","DOI":"10.18632\/oncotarget.7194","article-title":"Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"aal1645","DOI":"10.1126\/scitranslmed.aal1645","article-title":"Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.3390\/cancers14174162","article-title":"PARP1: Liaison of chromatin remodeling and transcription","volume":"14","author":"Zong","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1914271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:20:22Z","timestamp":1789042822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1914271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":66,"alternative-id":["10.3389\/fphar.2026.1914271"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1914271","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1914271"}}